What are the diagnostic and treatment approaches for a patient with diabetes insipidus?

Diagnosis and Treatment of Diabetes Insipidus

Diagnostic Approach

Suspect diabetes insipidus in any patient presenting with polyuria (>3 L/24h in adults), polydipsia, and inappropriately dilute urine (osmolality <200 mOsm/kg) combined with high-normal or elevated serum sodium—this triad is pathognomonic. 1

Initial Biochemical Work-Up

• Measure serum sodium, serum osmolality, and urine osmolality simultaneously as the first-line diagnostic tests 1, 2
• Obtain 24-hour urine volume to quantify polyuria 1
• Check serum creatinine and electrolytes (potassium, chloride, bicarbonate) 1
• The combination of urine osmolality <200 mOsm/kg with high-normal or elevated serum sodium confirms diabetes insipidus 1

Distinguishing Central from Nephrogenic DI

Plasma copeptin measurement is the primary differentiating test and should be obtained before proceeding to water deprivation testing. 3, 1

• Copeptin >21.4 pmol/L is diagnostic for nephrogenic diabetes insipidus in adults 3, 1
• Copeptin <21.4 pmol/L indicates either central diabetes insipidus or primary polydipsia and requires additional testing with hypertonic saline or arginine stimulation 3, 1
• This approach is superior to traditional water deprivation testing, which carries significant risks, particularly in children and patients with confirmed nephrogenic DI 2

Critical pitfall: The water deprivation test is contraindicated in patients with confirmed nephrogenic diabetes insipidus, especially infants and young children, due to significant risk of hypernatremic dehydration and neurological complications. 2 It is also contraindicated in patients with pre-existing hypernatremia (Na >145 mmol/L) or clinical dehydration. 2

Genetic Testing for Nephrogenic DI

Perform genetic testing early in all suspected cases of nephrogenic diabetes insipidus, even in adults and females. 3, 4

• Use a massively parallel sequencing-based multigene panel that includes at least AVPR2, AQP2, and AVP genes 3
• Include copy number variant analysis in the panel 3
• Genetic testing in umbilical cord blood is strongly recommended for male offspring of heterozygote AVPR2 mutation carriers to prevent primary manifestations through early treatment 3
• Approximately 10% of females with AVPR2 pathogenic variants develop the complete nephrogenic DI phenotype due to X-inactivation 3

Imaging Studies

Obtain MRI of the sella with dedicated pituitary sequences if central diabetes insipidus is suspected, as approximately 50% of cases have identifiable structural causes including tumors, infiltrative diseases, or inflammatory processes. 1

---

Treatment of Central Diabetes Insipidus

Desmopressin is the treatment of choice for central diabetes insipidus and can be administered via multiple routes (intranasal, oral, subcutaneous, or intravenous). 1, 5

Desmopressin Dosing

• Starting dose: 2-4 mcg daily administered as one or two divided doses by subcutaneous or intravenous injection 5
• Adjust morning and evening doses separately for adequate diurnal rhythm of water turnover 5
• For patients switching from intranasal desmopressin, start with 1/10th the daily maintenance intranasal dose 5
• Titrate dose based on adequate duration of sleep and adequate (not excessive) water turnover 5

Critical Monitoring for Hyponatremia

Desmopressin can cause life-threatening hyponatremia leading to seizures, coma, respiratory arrest, or death. 5

• Ensure serum sodium is normal before starting or resuming desmopressin 5
• Measure serum sodium within 7 days and at 1 month after initiating therapy, then periodically during treatment 1, 5
• Monitor more frequently in patients ≥65 years and those at increased risk of hyponatremia 5
• Initiate fluid restriction during treatment with desmopressin 5
• If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued 5

Contraindications

Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, including those with excessive fluid intake, illnesses causing fluid or electrolyte imbalances, and those using loop diuretics or systemic/inhaled glucocorticoids. 5

---

Treatment of Nephrogenic Diabetes Insipidus

Desmopressin is ineffective and not indicated for nephrogenic diabetes insipidus. 5 Treatment focuses on reducing urine output through dietary modifications and pharmacotherapy.

Fluid Management (Universal for All DI)

Patients with diabetes insipidus must have free access to fluid 24/7 to prevent dehydration, hypernatremia, growth failure, and constipation. 1, 4

• Patients capable of self-regulation should determine fluid intake based on thirst sensation rather than prescribed amounts, as their osmosensors are typically more sensitive and accurate than any medical calculation 1, 4
• Infants and toddlers cannot clearly express thirst and require caregivers to offer water frequently on top of regular fluid intake 1
• Individuals with cognitive impairment require close monitoring of weight, fluid balance, and biochemistry with proactive water offering 1

Critical pitfall: Never restrict water access in diabetes insipidus patients—this is a life-threatening error that leads to severe hypernatremic dehydration. 1

Dietary Modifications

Implement a low-salt diet (≤6 g/day) and protein restriction (<1 g/kg/day) with dietetic counseling to reduce renal osmotic load and minimize urine volume. 1, 4

• This dietary approach can reduce urine output by up to 50% when combined with pharmacotherapy 1
• Infants with nephrogenic DI should receive normal-for-age milk intake (not water) to ensure adequate caloric intake 1, 4
• Consider tube feeding in infants and children with repeated vomiting, dehydration, and/or failure to thrive 4

Pharmacological Treatment

For symptomatic infants and children with nephrogenic diabetes insipidus, start combination therapy with thiazide diuretics and prostaglandin synthesis inhibitors (NSAIDs). 1, 4

• Thiazide diuretics can reduce diuresis by up to 50% in the short term when combined with a low-salt diet 4
• Add amiloride to thiazide if hypokalemia develops 4
• Prostaglandin synthesis inhibitors are contraindicated during pregnancy 4
• Consider discontinuing NSAIDs once patients reach adulthood or achieve complete continence 4

Emergency Management

Each patient with nephrogenic DI should have an emergency plan including a letter explaining their diagnosis with advice regarding intravenous fluid management. 4

• For intravenous rehydration, use 5% dextrose in water (hypotonic fluid) at usual maintenance rates—NOT normal saline or electrolyte solutions 1, 4
• When fasting is required (>4 hours), administer intravenous 5% dextrose in water at maintenance rate with close monitoring 4
• Monitor clinical status including neurological condition, fluid balance, body weight, and serum electrolytes closely 4

---

Routine Follow-Up and Monitoring

Pediatric Patients (0-12 months)

• Clinical follow-up including weight and height measurements every 2-3 months 1
• Blood tests (sodium, potassium, chloride, bicarbonate, creatinine, uric acid) every 2-3 months 1
• Urinalysis including osmolality annually 1

Adult Patients

• Annual clinical follow-up including weight measurements 1
• Annual blood tests (sodium, potassium, chloride, bicarbonate, creatinine, uric acid) 1
• Annual urinalysis including osmolality, protein-creatinine or albumin-creatinine ratio, and 24-hour urine volume 1

Imaging Surveillance

Perform renal ultrasound at least every 2 years to monitor for urinary tract dilatation and/or bladder dysfunction from polyuria. 1, 4

• The interval can be extended to 5 years for stable patients 1
• Ultrasound should be performed before and after bladder emptying, as dilation improves with double voiding in approximately one-third of patients 1
• Approximately 46% of patients develop urological complications from chronic polyuria, including nocturnal enuresis and incomplete bladder voiding 1

Chronic Kidney Disease Risk

Patients with diabetes insipidus have an increased risk of chronic kidney disease, with approximately 50% of adult patients having CKD stage ≥2, requiring more frequent follow-up according to KDIGO guidelines. 1

Multidisciplinary Care

Patients should be managed by a multidisciplinary team including a (pediatric) nephrologist, dietitian, psychologist, social worker, and urologist. 1